Early detection of tumours is today a major challenge and requires sensitive imaging 24 methodologies coupled with new efficient probes. Bioluminescence imaging has been 25 widely used in the field of oncology and several cancer cell lines have been genetically 26 modified to provide bioluminescence signals. However, photons that are emitted by the 27 majority of commonly used luciferases are usually in the blue part of the visible 28 spectrum, where tissue absorption is still very high, making deep tissue imaging non-29 optimal and calling for optimised optical imaging methodologies. We have previously 30
Introduction 43 44 Imaging of physiological and pathological processes benefits from sensitive 45 methodologies [1] and new imaging probes and methodologies are constantly evolving 46 from the progress in preclinical research and important insights that it has yielded. 47
Preclinical and small-animal imaging modalities allow longitudinal and multiparametric 48 studies while reducing the number of animals used in the studies and thus comply with 49 ethical guidelines. They include MRI, SPECT, and PET [1, 2] . Whilst MRI and nuclear 50 imaging confer high resolution and sensitivity respectively, the cost of these scanners 51 and their maintenance represent major limitations in their use. By contrast, optical 52 imaging is a widely used and low-cost methodology, also offering high sensitivity but 53 also high throughput [3] . 54
Bioluminescence imaging has been widely used in the field of oncology. Several cell lines 55 have been genetically modified to provide both in vitro and in vivo stable 56 bioluminescence signals. In most cases, tumour cells are modified to express the enzyme 57 luciferase and then a suitable substrate is added exogenously, which leads to the 58 production of light in presence of oxygen and ATP [3, 4] . Recently, autonomous 59 bioluminescent mammalian cell lines have been developed. These cell lines express both 60 codon-optimised Photorhabdus luminescens luciferases coding genes and associated 61 genes responsible for the production and recycling of aldehyde and FMNH2 co-62 substrates required for light emission. As a direct consequence, these cell lines do not 63 require substrate addition to be luminescent [5] . Photon production in bioluminescence 64 is chemically dependent, provides high sensitivity and low background signals, and 65 unlike fluorescence does not require external excitation sources. However, the optical 66 spectral region where luciferases maximally emit is between 480 and 620 nm, where 67 tissue absorption is maximum, highly limiting deep tissue bioluminescence imaging [6, 68 3] while a range of wavelengths between 650 and 900 nm is more suitable for in vivo 69 imaging [7] . Several strategies have been developed in the last few years to overcome 70 this limitation by red-shifting the emission in the well-adapted wavelength range where 71 tissue absorption is minimal. One of the strategies adopted is the Bioluminescence 72
Resonance Energy Transfer (BRET). BRET is a non-radiative process in which energy is 73 transferred from a bioluminescent donor to a fluorescent acceptor that has been shown 74 to be a powerful tool to evaluate protein-protein interaction [8, 9] . Based on the 75 principle of BRET, self-illuminated quantum dots (QDs) have been designed [10] . QDs 76 are inorganic fluorescent nanocrystals that are ideal candidate as BRET acceptor due to 77 their broad absorbance spectra, high absorbance cross sections, high fluorescence 78 quantum yield and their large Stokes shift in the near infrared (NIR) region [11] . In this 79 context, carboxylate QDs coupled with amide luciferase and even functionalized with a 80 RGD peptide have been developed for targeting in vivo cancer cells [12] [13] [14] . 81
Recently, we reported Fluorescence by Unbound Excitation from Luminescence (FUEL) 82 as a mean to red-shift bioluminescence emission without requiring extremely close 83 contact between donor and acceptor like in BRET. FUEL is defined as a radiative transfer 84 between a bioluminescent source exciting nearby fluorophore [15, 16] . We have 85 hypothesized that FUEL could be a useful tool for the detection of tumours in vivo due to 86 two main advantages. Firstly, luciferase does not need to be grafted to the nanoparticles. 87
This would allow the use of smaller diameter nanoparticles, likely to have superior 88 pharmacokinetic properties in comparison to coupled larger nanoparticles [17, 18] . 89 Secondly, because in FUEL, QDs red-emission is spatially correlated with the 90 bioluminescence emission of tumour cells, it is a relevant mean to increase the 91 sensitivity of the signal in tissue and is a marker of proximity. 92
In this study, we used two different in vivo subcutaneous bioluminescent tumour models 93 to investigate the suitability of FUEL in detecting tumours. The first model was induced 94 by bioluminescent B16-F10 tumour cells expressing firefly luciferase [19] [20] [21] . These 95 cells will be referred here as B16-Luc2. The second tumour model established here was 96 a bioluminescent HEK293 model, a human embryonic kidney cell line expressing the lux 97 operon from bacteria and will hereon be referred as HEK-Lux. This cell type expresses 98 both the luciferase and enzymes required for the production of the substrate, and 99 therefore does not require further administration of substrate [5] . Using these two 100 models, we present and quantify the first in vivo FUEL experiments using near-infrared 101 emitting quantum dots to achieve a red-shifting emission of the subcutaneous tumours. The autobioluminescent HEK293 cells with the luxCDABE operon (HEK-Lux) cells were 108 kindly provided by 490 BioTech (Tennessee, USA) [22] . These cells were cultured at 109 37°C and 5% CO2 in DMEM with Glutamax and Pyruvate (Life technologies) 110 supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco), 1% of non-111 essential amino acids (Sigma), 1% penicillin/streptomycin (Life technologies) and 100 112 µg/mL G418 (Sigma). The experiments were performed with cells at passage 20 to 22. 113 Non-autobioluminescent HEK293 cells were cultured in the same medium as HEK-Lux 114 cells, but in the absence of antibiotic G418. At confluence, cells were rinsed with 115 phosphate buffered saline without Ca 2+ and Mg 2+ (PBS, Gibco) and harvested with 0.05% 116 trypsin-EDTA (Gibco). Cells were used at passage 9. 117
The melanoma cell line B16-F10, expressing Luc2 (B16-Luc2) was kindly provided by 118 the group of Pierre Bruhns (Institut Pasteur, Paris). The cells were cultured in RPMI 119 1640 with glutamine and Hepes (Gibco) supplemented with 10% heat-inactivated FBS 120 and 1% penicillin/streptomycin. At maximum 50% of confluence, cells were rinsed with 121 PBS and harvested with 0.05% trypsin-EDTA. The experiments were performed with 122 cells at passages between 6 and 16. 123
The emission spectra of the HEK-Lux and B16-Luc2 cells were determined using 2x10 5 124 cells suspended in 0.1 mL of appropriated medium. One day prior to imaging, cells were 125 In order to investigate the ability of FUEL to enhance the detection of tumours in vivo, 256 we used two distinct bioluminescent preclinical subcutaneous tumour models in nude 257 mice: murine B16-Luc2 melanoma tumours previously described [21] and the human 258 HEK 293 tumor model, adapted from the model described by Ho et al. [23] . 259
Firstly, we characterised the emission spectrum for each of the tumoral cell types and 260 observed an emission peak at 600 nm for B16-Luc2 (Fig 1A) , while for HEK-Lux the peak 261 was at 500 nm ( Fig 1B) . It is noteworthy that the B16-Luc2 cells emit a stronger 262 bioluminescent signal when compared to an equal number of HEK-Lux cells. B16-Luc2 263 cells also showed higher in vivo proliferation than HEK-Lux cells. While 8 x 10 4 B16-Luc2 264 cells induced the formation of 400 mm 3 tumours in 14 days ( Fig 1C) , 5 x10 6 HEK-Lux 265 cells were necessary to induced similar tumour sizes in more than 30 days ( Fig 1D) . We also acquired bioluminescence images of tumours over time, and observed that 277 similar to the growth in tumour volume, the bioluminescence signal intensity of B16-278
Luc2 tumours was detectable as early as 3 days post-injection and increased over time 279
to reach approximately 10 8 photons emitted/sec per tumour on day 14 (Fig 2A and 2C) . 280
In contrast, though HEK-Lux cells emitted a high bioluminescence signal immediately 281 after the subcutaneous injection, this signal disappeared on day 1. The signal stayed low 282 until day 29, when it started to increase again, reaching a maximum of 10 5 photons/sec 283 per tumour on day 38 ( Fig 2B and 2D) . Interestingly, the signal increase correlated with 284 the development of the tumour, as assessed by an increase in tumour volume, 285 suggesting that the cells had a latency time before growing and emitting higher 286 bioluminescence signal. Altogether, these observations show that the two tumour 287 models have markedly different growth curves and that the B16-Luc2 tumours emit 288 1000 times more light using an open filter for detection than the HEK-Lux. 289 Lux-induced tumours (Fig 3A and 3B) . Mice not bearing tumours were used as control, 305 and did not show fluorescence signal in the upper abdomen. The fluorescence signal 306 observed in the lower abdomen, in both control and tumour-bearing mice, is likely 307 associated with the renal excretion of the probe. In order to investigate the 308 vascularization at microscopic levels, we have administrated high molecular weight 309 dextran labelled with FITC i.v. Corroborating the results in vivo, histological sections 310 suggest that the vascularization is similar in both tumour models (Fig 3C and 3D) . The photoluminescence quantum yield was estimated at 20-30% using ICG in DMSO as a 338 standard fluorophore. Based on these spectra, we first investigated the presence of FUEL 339 with both B16-Luc2 and HEK-Lux in vitro. The incubation of B16-Luc2 cells with NIR 340 QDs significantly increased the bioluminescence signal at 840 nm as compared to cells 341 alone, and B16-Luc2 incubated with NIR QDs but in the absence D-luciferin ( Fig 4B) . 342
Normalized SSMD values classified the FUEL phenomenon extremely strong as 343 compared to the controls (Fig 4C) . HEK-Lux cells, which emit weaker bioluminescence 344 signals, also showed an increase in the intensity of bioluminescence at 840 nm in the 345 presence of NIR QDs. The statistical analyses using SSMD normalization indicate a very 346 strong difference between HEK-Lux cells incubated with NIR QDs and controls (HEK-Lux 347 cells alone, and non-bioluminescent HEK cells incubated with NIR QDs) ( Fig 4D) . It is 348 important to mention that the scales for B16-Luc2 and HEK-Lux are different due to the 349 intensity of the bioluminescence emitted by each cell types. The presence of NIR QDs in 350 the specified wells was confirmed by the fluorescence images ( Fig 4B) . way is vital to support the search for new therapies in oncology. In this study, we used 398 two different bioluminescent tumour models to demonstrate for the first time, that the 399 FUEL process can be used in vivo to red-shift bioluminescence tumour emission and 400 enhance the detection of tumours. 401
Herein, we established two murine models of tumours to investigate FUEL. One of the 402 models was xenogeneic and made use of human (HEK-Lux) cells, an autobioluminescent 403 cell type [5] . The second model was syngeneic, induced by B16-Luc2, a murine 404 melanoma cell type expressing the enzyme luciferase frequently used in preclinical 405 oncology [27] . While B16-Luc2 tumour growth and their bioluminescence signal showed 406 the same profile, HEK-Lux cells initially presented a high bioluminescence activity 407 immediately after the subcutaneous injection before showing a marked decrease of this 408 activity the following day. We believe that these cells needed to adapt to the new 409 environment before propagating and forming the solid tumour. After this latency period, 410 the tumours reached the maximal volume that corresponded with the second peak of 411 bioluminescence emission. 412
Each of the developed models has advantages and disadvantages with regard to FUEL 413 applications. HEK-Lux cells have the enormous advantage of being autobioluminescent 414 due to its constitutive expression of the bacterial lux operon thus enabling convenient 415 image acquisition without having to consider the biodistribution kinetics of exogenously 416 added substrate in vitro or in vivo [5] as for the B16-Luc2 cells [20] . This required 417 substrate injection is a limitation since the time between substrate injection and imaging 418 needs to be strictly controlled to achieve reproducibility in the data, mainly when 419 acquiring images using different emission filters before and after the injection of NIR 420
QDs. In addition, melanin production by the B16-Luc2 cells might be a concern for this 421 type of imaging. However, we observed that melanin expression becomes significant 422 only 2 weeks after subcutaneous injection, after we performed our experiments, and 423 that these cells are indeed suited for FUEL imaging (Fig. 5) . 424 FUEL is a phenomenon that allows the red shifting of the light, enhancing the detection 425 of bioluminescent tumours because of the reduction of tissue absorption and scattering 426 of blue/green light. One of the requirements for effective FUEL is that the fluorophore 427 should have a large Stokes shift, determining the requirement of an ideal bioluminescent 428 emitting source at approximately 500 nm [15, 16] . In this context, the wavelength of the 429 maximal bioluminescence emission peak of HEK-Lux cells would be another advantage 430 over B16-Luc2 cells regarding FUEL. Indeed, HEK-Lux cells emit luminescence at a 431 maximum peak of 490 nm [5] . By contrast, B16-Luc2 cells have a maximum emission 432 peak at 600 nm. In our case, we were still able to observe FUEL with B16-Luc2 because 433 we used NIR QDs, which have a large absorption range. Furthermore, B16-Luc2 cells 434 showed much stronger bioluminescence signal intensity in comparison to HEK-Lux cells, 435 requiring shorter exposure times during imaging and overall higher FUEL efficiency. Our 436 results show that even if HEK-Lux cells have a more appropriate maximum emission 437 wavelength to excite NIR QDs than B16-Luc cells, due to their lower luminescence 438 intensity, the red-shifting emission is not optimal. Indeed, if we focus on the maximum 439 emission wavelength of both cell types, 500 nm and 600 nm for HEK-Lux cells and B16-440
Luc2 cells respectively, NIR QDs absorb 4 times less at 600 nm than at 500 nm ( Fig 4A) . 441
However, the emission of B16-Luc2 cells is about 800 times higher at their maximum 442 emission wavelength compared to HEK-Lux emission at their maximum emission 443 wavelength (when the same number of cells are compared). Even at 500 nm, B16-Luc2 444 emission is 14 times higher than HEK-Lux cells, for the same number of cells ( Fig 4B) . 445
These results highlight the fact that FUEL efficiency is controlled by a combination of 446 both luminescence spectrum and intensity and acceptor absorbance properties. NIR QDs 447 have many advantages for FUEL applications; namely high excitation coefficient and 448 photoluminescence quantum yield. Moreover, this specific type of NIR QD has been 449 shown to provide a lower in vivo toxicity compared to classical NIR QDs mainly because 450 they are not composed of heavy metals [28] . In addition, FUEL efficiency also depends 451 on the imaging conditions. The emission filters used in this study have a 20 nm 452 bandwidth, which limits the imaging of the red-shifted emission photons. nanoparticles with switchable charge based on environmental stimulus [29, 31] . In our 475 study, the i.v. injection of NIR QDs 0.05 nmol in our models did not result in tumour 476 retention, suggesting the absence of the EPR effect under our experimental conditions 477 ( Supplementary Figure 1) . We have shown that both tumour models are similarly 478 vascularised, which allows us to suggest that, with some improvement in our 479 experimental conditions, NIR QDs could reach the tumours via i.v. administration. One 480 alternative would be the targeting of tumours by coupling the nanoparticles with 481 antibodies or peptides. RGD (Arg-Gly-Asp) is a triple-peptide motif that has affinity 482 binding to the integrin αvβ3, which is highly expressed in neovasculature and many 483 tumour lines [32] and nanoparticles coupled to RGD have been shown to target tumours 484 and improve their visualization [33] . Antibody-coupled nanoparticles have also been 485 used for specific targeting of the tumour in preclinical imaging. NIR QDs or iron oxides 486 nanoparticles coupled to anti-HER2 showed high specificity in targeting subcutaneous 487 ovarian and prostate xenografts [34] . The NIR QDs used here could also be conjugated to 488 antibodies and/or targeting peptides like RGD to ensure accumulation in tumours and 489 provide more suitable experimental conditions to detect metastasis and deep tumours. 490
In summary, we have shown the development of two different tumour models and FUEL 491 ability to red shifting their emission. With further improvements, this optical method 492 could offer an attractive alternative for detecting smaller and deeper tumours. 
